Treatment of Bolivian hemorrhagic fever with intravenous ribavirin

Clinical Infectious Diseases

Volumn 24, Issue 4, 1997, Pages 718-722

  Kilgore, Paul E ^b   Ksiazek, Thomas G ^b   Rollin, Pierre E ^b   Mills, James N ^b   Villagra, Mario R ^b   Montenegro, Mario J ^b   Costales, Maria A ^b   Paredes, Luis C ^b   Peters, C J ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RIBAVIRIN;

ADULT; ARTHRALGIA; ARTICLE; BOLIVIA; CASE REPORT; CLINICAL FEATURE; DISEASE TRANSMISSION; EPIDEMIC; EPISTAXIS; FEVER; HEADACHE; HEMATEMESIS; HEMATURIA; HEMORRHAGIC FEVER; HOSPITAL INFECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MELENA; MYALGIA; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0030935067     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clind/24.4.718     Document Type: Article

References (18)

1. MacKenzie RB. Epidemiology of Machupo viras infection. I. Patterns of human infection, San Joaquín, Bolivia, 1962-1964. Am J Trop Med Hyg 1965;14:808-13.
2. Webb PA, Justines G, Johnson KM. Infection of wild and laboratory animals with Machupo and Latino viruses. Bull WHO 1975;52:493-9.
3. Peters CJ, Kuehne RW, Mercado RR, Le Bow RH, Spertzel RO, Webb PA. Hemorrhagic fever in Cochabamba, Bolivia, 1971. Am J Epidemiol 1974;99:425-33.
4. Stinebaugh BJ, Schloeder FX, Johnson KM, Mackenzie RB, Entwisle G, DeAlba E. Bolivian hemorrhagic fever: a report of four cases. Am J Med 1966;40:217-30.
5. McCormick JB, King IJ, Webb PA, et al. Lassa fever: effective therapy with ribavirin. N Engl J Med 1986;314:20-6.
6. Peters CJ, Jahrling PB, Liu CT, Kenyon RH, McKee KT Jr, Barrera-Oro JG. Experimental studies of arenaviral hemorrhagic fevers. In: Oldstone MB, ed. Current topics in microbiology and immunology. Vol. 134. Arenaviruses: epidemiology and immunotherapy, Heidelberg, Germany: Springer-Verlag, 1987:5-68.
7. Enria DA, Maiztegui JI. Antiviral treatment of Argentine hemorrhagic fever. Antiviral Res 1994;23:23-31.
8. MacKenzie RB, Beye HK, Valverde L, Garron H. Epidemic hemorrhagic fever in Bolivia. I. A preliminary report on the epidemiologic and clinical findings in a new epidemic area in South America. Am J Trop Med Hyg 1964;13:620-5.
9. Patterson JL, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990;12:1139-46.
10. Stephen EL, Jones DE, Peters CJ, Eddy GA, Loizeaux PS, Jahrling PB. Ribavirin treatment of toga-, arena-, and bunyavirus infection in subhuman primates and other laboratory animal species. In: Smith RA, Kirkpatrick W, eds. Ribavirin: a broad spectrum antiviral agent. New York: Academic Press, 1980:169-83.
11. Kenyon RH, Canonico PG, Green DE, Peters CJ. Effect of ribavirin and tributylribavirin on argentine hemorrhagic fever (Junin virus) in guinea pigs. Antimicrob Agents Chemother 1986;29:521-3.
12. Weissenbacher MC, Calello MA, Colillas OJ, Rondinone SN, Frigerio MM. Argentine hemorrhagic fever: a primate model. Intervirology 1979;11:363-5.
13. Huggins JW, Hsiang CM, Cosgriff TM, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 1991;164:1119-27.
14. Canonico PG, Kastello MD, Cosgriff TM, et al. Hematological and bone marrow effects of ribavirin in rhesus monkeys. Toxicol Appl Pharmacol 1984;74:163-72.
15. Canonico PG. A review of efficacy, toxicity and mechanism of antiviral activity. In: Hahn FE, ed. Antibiotics. Vol 6. Modes and mechanisms of microbial growth inhibitors. New York: Springer-Verlag, 1983:161-86.
16. Barry M, Russi M, Armstrong L, et al. Brief report: treatment of a laboratory-acquired Sabia virus infection. N Engl J Med 1995;333:294-6.
17. Child PL, MacKenzie RB, Valverde LR, Johnson KM. Bolivian hemorrhagic fever: a pathologic description. Arch Pathol 1967;83:434-45.
18. Enria D, Franco SG, Ambrosio A, Vallejos D, Levis S, Maiztegui J. Current status of the treatment of Argentine homorrhagic fever. Med Microbiol Immunol 1986;175:173-6.